IRCT20220209053979N1尚未招募未知
A cross over bioequivalence study of Rivaroxaban 20 mg tab compared to Xarelto 20 mg tab manufactured by Bayer 24 healthy volunteers under fasting condition
Pars Darou0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •Have no history of heart, liver, kidney, lung, coagulation disorders
- •They have not taken any medication at least one month before starting the study
排除标准
- •Systolic blood pressure above 13 and below 10 and diastolic blood pressure below 6 and above 85 mm Hg
- •heart rate more than 90 or less than 60 beats per minute
研究者
相似试验
尚未招募
不适用
In-vivo Bioequivalence Test of Rivaroxaban® tablet with brand drugs (Xarelto® Bayer, Germany).IRCT20200105046010N27Jaber Ibn Hayyan Pharmaceutical Company24
尚未招募
Unknown
Bioequivalence study of Rivaroxaban 20mg tabletIRCT20200623047902N28Darou Darman Arang company24
招募中
不适用
Bioequivalence study of Rivaroxaban 20 mg tabletBioequivalence study of Rivaroxaban 20 mg tablet (Tehran Darou) versus Xalerto® 20 mg (Bayer) Tablet after single oral dosing in healthy volunteers.IRCT20220111053692N4tehran darou Pharmaceutical Company24
已完成
1 期
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male SubjectsEmbolism, Atrial Fibrillation and Venous ThrombosisNCT02537405Bayer40
已完成
1 期
Bioequivalence Study of RivaroxabanEmbolism, Atrial Fibrillation and Venous ThrombosisNCT02537457Bayer40